Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O. Maura F, et al. Among authors: korde n. Nat Cancer. 2023 Dec;4(12):1660-1674. doi: 10.1038/s43018-023-00657-1. Epub 2023 Nov 9. Nat Cancer. 2023. PMID: 37945755
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma.
Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, Hassoun H, Mailankody S, Shah U, Maclachlan K, Patel D, Lahoud O, Landau H, Chung D, Shah G, Scordo M, Giralt S, Lesokhin A, Usmani S, Landgren O, Korde N. Tan CR, et al. Among authors: korde n. Res Sq [Preprint]. 2023 Feb 24:rs.3.rs-2583053. doi: 10.21203/rs.3.rs-2583053/v1. Res Sq. 2023. Update in: Blood Cancer J. 2023 Jul 25;13(1):112. doi: 10.1038/s41408-023-00882-y PMID: 36865246 Free PMC article. Updated. Preprint.
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Firestone RS, Socci ND, Shekarkhand T, Zhu M, Qin WG, Hultcrantz M, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah U, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Usmani SZ, Chung DJ. Firestone RS, et al. Among authors: korde n. Blood. 2024 Jul 25;144(4):402-407. doi: 10.1182/blood.2023023557. Blood. 2024. PMID: 38728378
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies.
Howard AJ, Concepcion I, Wang AX, Hamadeh IS, Hultcrantz M, Mailankody S, Tan C, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Chung DJ, Giralt S, Usmani SZ, Firestone RS. Howard AJ, et al. Among authors: korde n. Blood Adv. 2024 Jun 25;8(12):3246-3253. doi: 10.1182/bloodadvances.2024012871. Blood Adv. 2024. PMID: 38621239 Free PMC article.
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.
Nath K, Shekarkhand T, Salcedo M, Derkach A, Rueda S, Chansakul A, Hulcrantz M, Korde N, Shah UA, Tan C, Chung DJ, Lahoud OB, Hassoun H, Lesokhin AM, Landau HJ, Shah G, Scordo M, Giralt SA, Usmani SZ, Roshal M, Landgren O, Mailankody S. Nath K, et al. Among authors: korde n. Leuk Lymphoma. 2022 Dec;63(14):3488-3492. doi: 10.1080/10428194.2022.2131417. Epub 2022 Oct 25. Leuk Lymphoma. 2022. PMID: 36282633 No abstract available.
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.
Laracy JC, Yan J, Steiger SN, Tan CA, Cohen N, Robilotti EV, Fender J, Cohen S, Korde N, Lee-Teh M, Noy A, Oved JH, Roeker LE, Shah G, Babady NE, Kamboj M, Seo SK. Laracy JC, et al. Among authors: korde n. Haematologica. 2023 Nov 1;108(11):3058-3067. doi: 10.3324/haematol.2023.283015. Haematologica. 2023. PMID: 37345467 Free PMC article.
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
Shah UA, Moshier E, Derkach A, Huang Y, Mailankody S, Tan CR, Maclachlan K, Hultcrantz M, Korde N, Hassoun H, Thibaud S, Sanchez L, Rodriguez C, Richard S, Richter J, Rossi A, Cho HJ, Lesokhin A, Chari A, Usmani SZ, Jagannath S, Parekh S, Gallagher EJ. Shah UA, et al. Among authors: korde n. Blood Adv. 2024 Jan 9;8(1):236-247. doi: 10.1182/bloodadvances.2023010815. Blood Adv. 2024. PMID: 37772981 Free PMC article.
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma.
Lesokhin A, Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, Farzana T, Rueda C, Chung D, Landau H, Lahoud O, Scordo M, Shah G, Hassoun H, Maclachlan K, Korde N, Shah U, Tan CR, Hultcrantz M, Giralt S, Usmani S, Shahid Z, Mailankody S. Lesokhin A, et al. Among authors: korde n. Res Sq [Preprint]. 2024 Feb 7:rs.3.rs-3911922. doi: 10.21203/rs.3.rs-3911922/v1. Res Sq. 2024. Update in: Blood Cancer J. 2024 May 31;14(1):88. doi: 10.1038/s41408-024-01043-5 PMID: 38405866 Free PMC article. Updated. Preprint.
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, Hassoun H, Mailankody S, Shah U, Maclachlan K, Patel D, Lahoud OB, Landau HJ, Chung DJ, Shah GL, Scordo M, Giralt SA, Lesokhin A, Usmani SZ, Landgren O, Korde N. Tan CR, et al. Among authors: korde n. Blood Cancer J. 2023 Jul 25;13(1):112. doi: 10.1038/s41408-023-00882-y. Blood Cancer J. 2023. PMID: 37491332 Free PMC article.
121 results